Martijn J. Schuemie

Martijn J. Schuemie

Auto-generated profile, based on publicly available information

Martijn J. Schuemie

Department of Biostatistics, University of Clifornia, Los Angeles, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015
Verified
Journal Article
Closed access
GHGeorge Hripcsak
George Hripcsak
JDJon D Duke
Jon D Duke
NSNigam H Shah
Nigam H Shah
CRChristian G Reich
Christian G Reich
VHVojtech Huser
Vojtech Huser
PRPatrick B Ryan
Patrick B Ryan

10 February 2015 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
EVErica A Voss
Erica A Voss
RMRupa Makadia
Rupa Makadia
AMAmy Matcho
Amy Matcho
QMQianli Ma
Qianli Ma
CKChris Knoll
Chris Knoll
PRPatrick B Ryan
Patrick B Ryan
Objectives To evaluate the utility of applying the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) across multiple observational databases within an organization and to apply standardized analytics tools for conducting observational research. Materials and methods Six deidentified patient-level datasets were transformed to the OMOP CDM. We evaluated the extent of information loss that occurred through the standardization process. We developed a standardized analytic tool to replicate the cohort construction process from a published epidemiology protocol and applied the analysis to all 6 databases to assess time-to-execution and comparability of results. Results Transformation to the CDM resulted in minimal information loss across all 6 databases. Patients and observations excluded were due to identified data quality issues in the source system, 96% to 99% of condition records and 90% to 99% of drug records were successfully mapped into the CDM using the standard vocabulary. The full cohort replication and descriptive baseline summary was executed for 2 cohorts in 6 databases in less than 1 hour. Discussion The standardization process improved data quality, increased efficiency, and facilitated cross-database comparisons to support a more systematic approach to observational research. Comparisons across data sources showed consistency in the impact of inclusion criteria, using the protocol and identified differences in patient characteristics and coding practices across databases. Conclusion Standardizing data structure (through a CDM), content (through a standard vocabulary with source code mappings), and analytics can enable an institution to apply a network-based approach to observational research across multiple, disparate observational health databases.

1 May 2002 in Behaviour Research and Therapy
Verified
Journal Article
Closed access
PEP.M.G Emmelkamp
P.M.G Emmelkamp
MKM Krijn
M Krijn
AHA.M Hulsbosch
A.M Hulsbosch
SVS de Vries
S de Vries
MSM.J Schuemie
M.J Schuemie
CMC.A.P.G van der Mast
C.A.P.G van der Mast

6 June 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GHGeorge Hripcsak
George Hripcsak
PRPatrick B. Ryan
Patrick B. Ryan
JDJon D. Duke
Jon D. Duke
NSNigam H. Shah
Nigam H. Shah
RPRae Woong Park
Rae Woong Park
DMDavid Madigan
David Madigan
Observational research promises to complement experimental research by providing large, diverse populations that would be infeasible for an experiment. Observational research can test its own clinical hypotheses, and observational studies also can contribute to the design of experiments and inform the generalizability of experimental research. Understanding the diversity of populations and the variance in care is one component. In this study, the Observational Health Data Sciences and Informatics (OHDSI) collaboration created an international data network with 11 data sources from four countries, including electronic health records and administrative claims data on 250 million patients. All data were mapped to common data standards, patient privacy was maintained by using a distributed model, and results were aggregated centrally. Treatment pathways were elucidated for type 2 diabetes mellitus, hypertension, and depression. The pathways revealed that the world is moving toward more consistent therapy over time across diseases and across locations, but significant heterogeneity remains among sources, pointing to challenges in generalizing clinical trial results. Diabetes favored a single first-line medication, metformin, to a much greater extent than hypertension or depression. About 10% of diabetes and depression patients and almost 25% of hypertension patients followed a treatment pathway that was unique within the cohort. Aside from factors such as sample size and underlying population (academic medical center versus general population), electronic health records data and administrative claims data revealed similar results. Large-scale international observational research is feasible.

28 September 2016 in BMJ
Verified
Journal Article
Open access
PDF file
AAAndrea Arfè
Andrea Arfè
LSLorenza Scotti
Lorenza Scotti
CVCristina Varas-Lorenzo
Cristina Varas-Lorenzo
FNFederica Nicotra
Federica Nicotra
AZAntonella Zambon
Antonella Zambon
GCGiovanni Corrao
Giovanni Corrao
Objectives To investigate the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) and estimate the risk of hospital admission for heart failure with use of individual NSAIDs. Design Nested case-control study. Setting Five population based healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom). Participants Adult individuals (age ≥18 years) who started NSAID treatment in 2000-10. Overall, 92 163 hospital admissions for heart failure were identified and matched with 8 246 403 controls (matched via risk set sampling according to age, sex, year of cohort entry). Main outcome measure Association between risk of hospital admission for heart failure and use of 27 individual NSAIDs, including 23 traditional NSAIDs and four selective COX 2 inhibitors. Associations were assessed by multivariable conditional logistic regression models. The dose-response relation between NSAID use and heart failure risk was also assessed. Results Current use of any NSAID (use in preceding 14 days) was found to be associated with a 19% increase of risk of hospital admission for heart failure (adjusted odds ratio 1.19; 95% confidence interval 1.17 to 1.22), compared with past use of any NSAIDs (use >183 days in the past). Risk of admission for heart failure increased for seven traditional NSAIDs (diclofenac, ibuprofen, indomethacin, ketorolac, naproxen, nimesulide, and piroxicam) and two COX 2 inhibitors (etoricoxib and rofecoxib). Odds ratios ranged from 1.16 (95% confidence interval 1.07 to 1.27) for naproxen to 1.83 (1.66 to 2.02) for ketorolac. Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses (≥2 defined daily dose equivalents), although some confidence intervals were wide. Even medium doses (0.9-1.2 defined daily dose equivalents) of indomethacin and etoricoxib were associated with increased risk. There was no evidence that celecoxib increased the risk of admission for heart failure at commonly used doses. Conclusions The risk of hospital admission for heart failure associated with current use of NSAIDs appears to vary between individual NSAIDs, and this effect is dose dependent. This risk is associated with the use of a large number of individual NSAIDs reported by this study, which could help to inform both clinicians and health regulators.

30 July 2013 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
MSMartijn J. Schuemie
Martijn J. Schuemie
PRPatrick B. Ryan
Patrick B. Ryan
WDWilliam DuMouchel
William DuMouchel
MSMarc A. Suchard
Marc A. Suchard
DMDavid Madigan
David Madigan
Often the literature makes assertions of medical product effects on the basis of ‘ p < 0.05’. The underlying premise is that at this threshold, there is only a 5% probability that the observed effect would be seen by chance when in reality there is no effect. In observational studies, much more than in randomized trials, bias and confounding may undermine this premise. To test this premise, we selected three exemplar drug safety studies from literature, representing a case–control, a cohort, and a self‐controlled case series design. We attempted to replicate these studies as best we could for the drugs studied in the original articles. Next, we applied the same three designs to sets of negative controls: drugs that are not believed to cause the outcome of interest. We observed how often p < 0.05 when the null hypothesis is true, and we fitted distributions to the effect estimates. Using these distributions, we compute calibrated p‐values that reflect the probability of observing the effect estimate under the null hypothesis, taking both random and systematic error into account. An automated analysis of scientific literature was performed to evaluate the potential impact of such a calibration. Our experiment provides evidence that the majority of observational studies would declare statistical significance when no effect is present. Empirical calibration was found to reduce spurious results to the desired 5% level. Applying these adjustments to literature suggests that at least 54% of findings with p < 0.05 are not actually statistically significant and should be reevaluated. © 2013 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.